Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Dose-ranging Trial to Evaluate the Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Linezolid in Adult Subjects With Newly Diagnosed Drug-Sensitive, Smear-Positive Pulmonary Tuberculosis.

NCT02279875 is registered in ClinicalTrials.gov with Global Alliance for TB Drug Development as lead sponsor.

NCT NCT02279875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02279875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Dose-ranging Trial to Evaluate the Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Linezolid in Adult Subjects With Newly Diagnosed Drug-Sensitive, Smear-Positive Pulmonary Tuberculosis.
Lead sponsor
Global Alliance for TB Drug Development
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
July 31, 2017
Enrollment
113 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis